No retraction, correction or concern found when last checked on Nov 5, 2026.

A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics

Lauren Forchette, William Sebastian, Tuoen Liu

Current Medical Science · 2021 · Review · CC BY

Abstract

Summary Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of the coronavirus disease 2019 (COVID-19), has caused more than 179 million infections and 3.8 million deaths worldwide. Throughout the past year, multiple vaccines have already been developed and used, while some others are in the process of being developed. However, the emergence of new mutant strains of SARS-CoV-2 that have demonstrated immune-evading characteristics and an increase in infective capabilities leads to potential ineffectiveness of the vaccines against these variants. The purpose of this review article is to highlight the current understanding of the immunological mechanisms of the virus and vaccines, as well as to investigate some key variants and mutations of the virus driving the current pandemic and their impacts on current management guidelines. We also discussed new technologies being developed for the prevention, treatment, and detection of SARS-CoV-2. In this paper, we thoroughly reviewed and provided crucial information on SARS-CoV-2 virology, vaccines and drugs being used and developed for its prevention and treatment, as well as important variant strains. Our review paper will be beneficial to health care professionals and researchers so they can have a better understanding of the basic sciences, prevention, and clinical treatment of COVID-19 during the pandemic. This paper consists of the most updated information that has been available as of June 21, 2021.

References 88

1.
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433.
Not in our library10.1016/j.jaut.2020.102433
2.
Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2 · 2020
No notice
3.
Masters PS. Coronavirus genomic RNA packaging. Virology. 2019;537:198-207.
Not in our library10.1016/j.virol.2019.08.031
4.
Kaur N, Singh R, Dar Z, et al. Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2. Infect Genet Evol. 2021;89:104490.
Not in our library10.1016/j.meegid.2020.104490
5.
A pneumonia outbreak associated with a new coronavirus of probable bat origin · 2020
No notice
6.
Bai C, Warshel A. Critical Differences between the Binding Features of the Spike Proteins of SARS-CoV-2 and SARS-CoV. J Phys Chem B. 2020;124(28):5907-5912.
Not in our library10.1021/acs.jpcb.0c04317
7.
Huang Y, Yang C, Xu XF, et al. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141-1149.
Not in our library10.1038/s41401-020-0485-4
8.
SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity · 2021
No notice
9.
Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2) · 2020
No notice
10.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-80.
Not in our library10.1016/j.cell.2020.02.052
11.
Zhou Z, Zhao N, Shu Y, et al. Effect of Gastrointestinal Symptoms in Patients With COVID-19. Gastroenterology. 2020;158(8):2294-2297.
Not in our library10.1053/j.gastro.2020.03.020
12.
Prevalence, Mechanisms, and Implications of Gastrointestinal Symptoms in COVID-19 · 2020
Not checked
13.
Coronavirus Disease 2019 Hospitalizations Attributable to Cardiometabolic Conditions in the United States: A Comparative Risk Assessment Analysis · 2021
Not checked
14.
Caramelo F, Ferreira N, Oliveiros B. Estimation of risk factors for COVID-19 mortality— preliminary results. medRxiv, 2020,02.24.20027268
Not in our library
15.
Gheblawi M, Wang K, Viveiros A, et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020;126(10):1456-1474.
Not in our library10.1161/circresaha.120.317015
16.
Coperchini F, Chiovato L, Croce L, et al. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25.
Not in our library10.1016/j.cytogfr.2020.05.003
17.
Faqihi F, Alharthy A, Memish ZA, et al. Comment on Hu et al: The cytokine storm and COVID-19. J Med Virol. 2021;93(2):631-633.
Not in our library10.1002/jmv.26396
18.
Biswas S, Thakur V, Kaur P, et al. Blood clots in COVID-19 patients: Simplifying the curious mystery. Med Hypotheses. 2021;146:110371.
Not in our library10.1016/j.mehy.2020.110371
19.
Huang Q, Wu X, Zheng X, et al. Targeting inflammation and cytokine storm in COVID-19. Pharmacol Res. 2020;159:105051.
Not in our library10.1016/j.phrs.2020.105051
20.
Tay MZ, Poh CM, Rénia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020;20(6):363-374.
Not in our library10.1038/s41577-020-0311-8
21.
Zheng HY, Zhang M, Yang CX, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 2020;17(5):541-543.
Not in our library10.1038/s41423-020-0401-3
22.
Chowdhury MA, Hossain N, Kashem MA, et al. Immune response in COVID-19: A review. J Infect Public Health. 2020;13(11):1619-1629.
Not in our library10.1016/j.jiph.2020.07.001
23.
Lee WS, Wheatley AK, Kent SJ, et al. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. Nat Microbiol. 2020;5(10):1185-1191.
Not in our library10.1038/s41564-020-00789-5
24.
Tirado SM, Yoon KJ. Antibody-dependent enhancement of virus infection and disease. Viral Immunol. 2003;16(1):69-86.
Not in our library10.1089/088282403763635465
25.
Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies · 2021
Not checked
26.
Huang Q, Zeng J, Yan J. COVID-19 mRNA vaccines. J Genet Genomics. 2021;48(2):107-114.
Not in our library10.1016/j.jgg.2021.02.006
27.
Livingston EH, Malani PN, Creech CB. The Johnson & Johnson Vaccine for COVID-19. JAMA. 2021;325(15):1575.
Not in our library10.1001/jama.2021.2927
28.
Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA, 2021, e218565. doi: 10.1001/jama.2021.8565. Epub ahead of prrnt. PMID: 34037666; PMCID: PMC8156175.
Not in our library10.1001/jama.2021.8565
29.
Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39-51.
Not in our library10.1016/s1473-3099(20)30831-8
30.
Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(6):803-812.
Not in our library10.1016/s1473-3099(20)30987-7
31.
mRNA Vaccine Era—Mechanisms, Drug Platform and Clinical Prospection · 2020
No notice
32.
Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans · 2021
No notice
33.
Linares-Fernández S, Lacroix C, Exposito JY, et al. Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response. Trends Mol Med. 2020;26(3):311-323.
Not in our library10.1016/j.molmed.2019.10.002
34.
mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability · 2021
No notice
35.
Dyer O. Covid-19: EMA defends AstraZeneca vaccine as Germany and Canada halt rollouts. BMJ. 2021;373:n883.
Not in our library10.1136/bmj.n883
36.
Xia S, Duan K, Zhang Y, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020;324(10):951-960.
Not in our library10.1001/jama.2020.15543
37.
Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181-192.
Not in our library10.1016/s1473-3099(20)30843-4
38.
Golob JL, Lugogo N, Lauring AS, et al. SARS-CoV-2 vaccines: a triumph of science and collaboration. JCI Insight. 2021;6(9):149187.
Not in our library10.1172/jci.insight.149187
39.
Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845-1854.
Not in our library10.1016/s0140-6736(20)31208-3
40.
Mallapaty S. China’s COVID vaccines are going globalbut questions remain. Nature. 2021;593(7858):178-179.
Not in our library10.1038/d41586-021-01146-0
41.
Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021;397(10275):671-681.
Not in our library10.1016/s0140-6736(21)00234-8
42.
Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396(10255):887-897.
Not in our library10.1016/s0140-6736(20)31866-3
43.
Chung YH, Beiss V, Fiering SN, et al. COVID-19 Vaccine Frontrunners and Their Nanotechnology Design. ACS Nano. 2020;14(10):12 522-12 537.
Not in our library10.1021/acsnano.0c07197
44.
Wadman M. The long shot. Science. 2020;370(6517):649-653.
Not in our library10.1126/science.370.6517.649
45.
Medhi R, Srinoi P, Ngo N, et al. Nanoparticle-Based Strategies to Combat COVID-19. ACS Appl Nano Mater. 2020;3(9):8557-8580.
Not in our library10.1021/acsanm.0c01978
46.
Ashraf MU, Kim Y, Kumar S, et al. COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. Vaccines. 2021;9(2):171.
Not in our library10.3390/vaccines9020171
47.
Moore AC, Dora EG, Peinovich N, et al. Preclinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection. bioRxiv, 2020.09.04.283853; doi: 10.1101/2020.09.04.283853
Not in our library
48.
The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA · 2021
No notice
49.
Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers · 2021
No notice
50.
Mahmood N, Nasir SB, Hefferon K. Plant-Based Drugs and Vaccines for COVID-19. Vaccines. 2020;9(1):15.
Not in our library10.3390/vaccines9010015
51.
Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Medicine, 2021. doi: 10.1038/s41591-021-01377-8. Epub ahead of print. PMID: 34002089.
Not in our library10.1038/s41591-021-01377-8
52.
Wu K, Werner AP, Koch M, et al. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. N Engl J Med. 2021;384(15):1468-1470.
Not in our library10.1056/nejmc2102179
53.
COVID-19 evolution during the pandemic – Implications of new SARS-CoV-2 variants on disease control and public health policies · 2021
No notice
54.
Abdool Karim SS, de Oliveira T. New SARS-CoV-2 Variants—Clinical, Public Health, and Vaccine Implications. N Engl J Med. 2021;384(19):1866-1868.
Not in our library10.1056/nejmc2100362
55.
Zou J, Xie X, Fontes-Garfias CR, et al. The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccrne-elicited neutralization. NPJ Vaccines. 2021;6(1):44.
Not in our library10.1038/s41541-021-00313-8
56.
Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020;182(4):812-827.
Not in our library10.1016/j.cell.2020.06.043
57.
Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2021;592(7852):116-121.
Not in our library10.1038/s41586-020-2895-3
58.
Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021;27(5):917-924.
Not in our library10.1038/s41591-021-01318-5
59.
Shen X, Tang H, McDanal C, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Cell Host Microbe. 2021;29(4):529-539.
Not in our library10.1016/j.chom.2021.03.002
60.
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera · 2021
No notice
61.
Zhou H, Dcosta BM, Samanovic MI, et al. B.1.526 SARS-CoV-2 variants identified in New York City are neutralized by vaccine-elicited and therapeutic monoclonal antibodies. bioRxiv, 2021.03.24.436620; doi: 10.1101/2021.03.24.436620
Not in our library10.1128/mbio.01386-21
62.
Annavajhala MK, Mohri H, Zucker JE, et al. A Novel SARS-CoV-2 Variant of Concern, B.1.526, Identified in New York. medRxiv, 2021.02.23.21252259. doi: 10.1101/2021.02.23.21252259
Not in our library
63.
Greaney AJ, Loes AN, Crawford KHD, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021;29(3):463-476.
Not in our library10.1016/j.chom.2021.02.003
64.
Kuzmina A, Khalaila Y, Voloshin O, et al. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or postvaccination sera. Cell Host Microbe. 2021;29(4):522-528.
Not in our library10.1016/j.chom.2021.03.008
65.
Edara VV, Norwood C, Floyd K, et al. Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. Cell Host Microbe. 2021;29(4):516-521.
Not in our library10.1016/j.chom.2021.03.009
66.
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant · 2021
No notice
67.
Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med. 2021;384(20):1885-1898.
Not in our library10.1056/nejmoa2102214
68.
Toovey OTR, Harvey KN, Bird PW, et al. Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK. J Infect. 2021;82(5):e23-e4.
Not in our library10.1016/j.jinf.2021.01.025
69.
Sapkal G, Yadav PD, Ella R, et al. Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine. bioRxiv, 2021,04.30.441559. doi: 10.1101/2021.04.30.441559
Not in our library
70.
Garcia-Beltran WF, Lam EC, St Denis K, et al. Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv, 2021.02.14.21251704. doi: 10.1101/2021.02.14.21251704
Not in our library
71.
Hirotsu Y, Omata M. Discovery of SARS-CoV-2 strain of P.1 lineage harboring K417T/E484K/N501Y by whole genome sequencing in the city, Japan. medRxiv, 2021.02.24.21251892. doi: 10.1101/2021.02.24.21251892
Not in our library
72.
Antibody evasion by the P.1 strain of SARS-CoV-2 · 2021
No notice
73.
SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India · 2021
No notice
74.
Motozono C, Toyoda M, Zahradnik J, et al. An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity. bioRxiv, 2021.04.02.438288. doi: 10.1101/2021.04.02.438288
Not in our library
75.
Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv, 2021.03.07.21252647. doi: 10.1101/2021.03.07.21252647
Not in our library
76.
Nazir SUR, Nazir T, Sultana M, et al. The Potentially Recommended Pharmacotherapy for COVID-19. Altern Ther Health Med. 2021;27(S1):24-28.
Not in our library
77.
Drożdżal S, Rosik J, Lechowicz K, et al. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy. Drug Resist Updat. 2020;53:100719.
Not in our library10.1016/j.drup.2020.100719
78.
Mechanism of SARS-CoV-2 polymerase stalling by remdesivir · 2021
No notice
79.
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19—Final Report. N Engl J Med. 2020;383(19):1813-1826.
Not in our library10.1056/nejmoa2007764
80.
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A · 2021
No notice
81.
Martinez MA. Plitidepsin: a Repurposed Drug for the Treatment of COVID-19. Antimicrob Agents Chemother. 2021;65(4):e00200-21.
Not in our library10.1128/aac.00200-21
82.
Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol. 2021;6(1):11-18.
Not in our library10.1038/s41564-020-00835-2
83.
Gottlieb RL, Nirula A, Chen P, et al. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2021;325(7):632-644.
Not in our library10.1001/jama.2021.0202
84.
Deb P, Molla MMA, Saif-Ur-Rahman KM. An update to monoclonal antibody as therapeutic option against COVID-19. Biosafety Health. 2021;3(2):87-91.
Not in our library10.1016/j.bsheal.2021.02.001
85.
Li R, Ma X, Deng J, et al. Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques. Cell Mol Immunol. 2021;18(4):1058-1060.
Not in our library10.1038/s41423-021-00641-8
86.
Acharya KP, Ghimire TR, Subramanya SH. Access to and equitable distribution of COVID-19 vaccine in low-income countries. NPJ Vaccines. 2021;6(1):54.
Not in our library10.1038/s41541-021-00323-6
87.
Quast I, Tarlinton D. B cell memory: understanding COVID-19. Immunity. 2021;54(2):205-210.
Not in our library10.1016/j.immuni.2021.01.014
88.
Rahimi H, Salehiabar M, Barsbay M, et al. CRISPR Systems for COVID-19 Diagnosis. ACS Sens. 2021;6(4):1430-1445.
Not in our library10.1021/acssensors.0c02312

Cited by papers we hold 2

РАЗРАБОТКА ВАКЦИН ОТ SARS-COV-2 · 2022
Not checked
The second year of pandemic in the Arctic: examining spatiotemporal dynamics of the COVID-19 “Delta wave” in Arctic regions in 2021 · 2022
Not checked

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.